The CenterWatch Weekly, January 23, 2017
FDA, IBM partner on the secure exchange of clinical data
Secure storage and controlled access to sensitive patient data are critical aspects of the clinical trial process. Investigators may need to access huge data sets shared across national and international sites. The amount and sheer number of types of data is rapidly increasing as the use of mobile and wearable devices and the querying of genomic databases are incorporated into trial design. Recently the FDA and IBM Watson Health announced a joint two-year research initiative that takes data sharing even further.
Sarah Cannon buys Genospace in precision medicine-based move
Sarah Cannon, the cancer institute of Hospital Corporation of America (HCA), has agreed to buy precision medicine software company Genospace in a pioneering deal that will allow for a more effective use of molecular profiling data to match cancer patients to clinical trials. Financial terms of the agreement, which is expected to close in the first quarter of this year, were not disclosed. Led by Genospace CEO Mick Correll, the company will become a wholly owned subsidiary of Sarah Cannon.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.